170 related articles for article (PubMed ID: 24772915)
1. Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
Mani E; Medina LA; Isaac-Olivé K; Dueñas-González A
Eur J Gynaecol Oncol; 2014; 35(2):140-2. PubMed ID: 24772915
[TBL] [Abstract][Full Text] [Related]
2. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death.
Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Fukunaga S; Futani H; Okamura H; Terada N
Int J Oncol; 2012 Jul; 41(1):83-91. PubMed ID: 22576685
[TBL] [Abstract][Full Text] [Related]
4. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
de la Cruz-Hernández E; Pérez-Cárdenas E; Contreras-Paredes A; Cantú D; Mohar A; Lizano M; Dueñas-González A
Virol J; 2007 Feb; 4():18. PubMed ID: 17324262
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
De la Cruz-Hernández E; Perez-Plasencia C; Pérez-Cardenas E; Gonzalez-Fierro A; Trejo-Becerril C; Chávez-Blanco A; Taja-Chayeb L; Vidal S; Gutiérrez O; Dominguez GI; Trujillo JE; Duenas-González A
Oncol Rep; 2011 Feb; 25(2):399-407. PubMed ID: 21152880
[TBL] [Abstract][Full Text] [Related]
6. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
Arce C; Pérez-Plasencia C; González-Fierro A; de la Cruz-Hernández E; Revilla-Vázquez A; Chávez-Blanco A; Trejo-Becerril C; Pérez-Cárdenas E; Taja-Chayeb L; Bargallo E; Villarreal P; Ramírez T; Vela T; Candelaria M; Camargo MF; Robles E; Dueñas-González A
PLoS One; 2006 Dec; 1(1):e98. PubMed ID: 17183730
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.
Chavez-Blanco A; Perez-Plasencia C; Perez-Cardenas E; Carrasco-Legleu C; Rangel-Lopez E; Segura-Pacheco B; Taja-Chayeb L; Trejo-Becerril C; Gonzalez-Fierro A; Candelaria M; Cabrera G; Duenas-Gonzalez A
Cancer Cell Int; 2006 Jan; 6():2. PubMed ID: 16448574
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer.
Candelaria M; Cetina L; Pérez-Cárdenas E; de la Cruz-Hernández E; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Chanona J; Arias D; Dueñas-González A
Eur J Gynaecol Oncol; 2010; 31(4):386-91. PubMed ID: 20882878
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Shoji M; Ninomiya I; Makino I; Kinoshita J; Nakamura K; Oyama K; Nakagawara H; Fujita H; Tajima H; Takamura H; Kitagawa H; Fushida S; Harada S; Fujimura T; Ohta T
Int J Oncol; 2012 Jun; 40(6):2140-6. PubMed ID: 22469995
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.
Coronel J; Cetina L; Pacheco I; Trejo-Becerril C; González-Fierro A; de la Cruz-Hernandez E; Perez-Cardenas E; Taja-Chayeb L; Arias-Bofill D; Candelaria M; Vidal S; Dueñas-González A
Med Oncol; 2011 Dec; 28 Suppl 1():S540-6. PubMed ID: 20931299
[TBL] [Abstract][Full Text] [Related]
11. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Candelaria M; Herrera A; Labardini J; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Pérez-Cárdenas E; de la Cruz-Hernández E; Arias-Bofill D; Vidal S; Cervera E; Dueñas-Gonzalez A
Ann Hematol; 2011 Apr; 90(4):379-87. PubMed ID: 20922525
[TBL] [Abstract][Full Text] [Related]
12. Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments.
Harikrishnan KN; Karagiannis TC; Chow MZ; El-Osta A
Cell Cycle; 2008 Feb; 7(4):468-76. PubMed ID: 18239454
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Candelaria M; Gallardo-Rincón D; Arce C; Cetina L; Aguilar-Ponce JL; Arrieta O; González-Fierro A; Chávez-Blanco A; de la Cruz-Hernández E; Camargo MF; Trejo-Becerril C; Pérez-Cárdenas E; Pérez-Plasencia C; Taja-Chayeb L; Wegman-Ostrosky T; Revilla-Vazquez A; Dueñas-González A
Ann Oncol; 2007 Sep; 18(9):1529-38. PubMed ID: 17761710
[TBL] [Abstract][Full Text] [Related]
14. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
[TBL] [Abstract][Full Text] [Related]
15. Effect of DNA Methyltransferase in Comparison to and in Combination with Histone Deacetylase Inhibitors on Hepatocellular Carcinoma HepG2 Cell Line.
Sanaei M; Kavoosi F
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1119-1125. PubMed ID: 31030484
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells.
Kumanishi S; Yamanegi K; Nishiura H; Fujihara Y; Kobayashi K; Nakasho K; Futani H; Yoshiya S
Int J Oncol; 2019 Jul; 55(1):167-178. PubMed ID: 31180533
[TBL] [Abstract][Full Text] [Related]
17. Effective and new potent drug combination: Histone deacetylase and Wnt/β-catenin pathway inhibitors in lung carcinoma cells.
Akgun O; Erkisa M; Ari F
J Cell Biochem; 2019 Sep; 120(9):15467-15482. PubMed ID: 31037769
[TBL] [Abstract][Full Text] [Related]
18. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
Candelaria M; Burgos S; Ponce M; Espinoza R; Dueñas-Gonzalez A
Ann Hematol; 2017 Nov; 96(11):1825-1832. PubMed ID: 28831600
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid.
Mora-García Mde L; Duenas-González A; Hernández-Montes J; De la Cruz-Hernández E; Pérez-Cárdenas E; Weiss-Steider B; Santiago-Osorio E; Ortíz-Navarrete VF; Rosales VH; Cantú D; Lizano-Soberón M; Rojo-Aguilar MP; Monroy-García A
J Transl Med; 2006 Dec; 4():55. PubMed ID: 17192185
[TBL] [Abstract][Full Text] [Related]
20. The epigenetic modifier, valproic acid, enhances radiation sensitivity.
Karagiannis TC; Kn H; El-Osta A
Epigenetics; 2006; 1(3):131-7. PubMed ID: 17965607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
